에 대한 최신 뉴스 Real Good Food Co (NASDAQ:RGF) 주식

The Real Good Food

The Real Good Food Co Inc is a frozen food company that develops, markets, and manufactures foods high in protein, low in sugar, and gluten- and grain-free. The company produces breakfast sandwiches, entrees, and other products, primarily sold in the U.S. frozen food category. All of its revenue is derived from the United States.

News

Penny Stocks

After-Hours Center

Movers

리얼 굿 푸드 컴퍼니(NASDAQ:RGF) 주식은 회사가 PMC 파이낸셜 서비스 및 엔블럼 인베스트먼트 펀드(Emblem Investment Fund)와의 부채 재융자 거래를 발표한 후 목요일 시간외 거래에서 70% 이상 급등했다. 이는 6,000만 달러의 새로운 장기 대출을 위한 거래이다.

리얼 굿 푸드 컴퍼니의 주식이 목요일 시간외 거래에서 70% 이상 급등: 무슨 일이?

The Real Good Food Company, Inc. - Class A Common Stock

The Real Good Food Co Inc

<p>A few decades ago, you'd made it if you hit that magic million-dollar mark. You were rich. These days, though, with skyrocketing costs and social media awash with luxury-laden highlights, it can feel like everyone's got a cool million in their back pocket. The truth? That's more illusion than reality. As <a href="https://www.benzinga.com/personal-finance/24/03/37520117/dave-ramsey-reveals-people-arent-as-well-off-as-you-think-8-out-of-10-people-probably-cant-affor">financial guru Dave Ramsey put it</a>: "8 out of 10 people probably can't afford the home they're living in and the car they're driving."</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich"><strong>Are you rich?</strong></a><strong> Here&#8217;s what Americans think you need to be considered wealthy.</strong></li>
<li><strong>Many are using this retirement income calculator to check if they&#8217;re on pace —</strong><a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"><strong> </strong><strong>here&#8217;s a breakdown on how on what&#8217;s behind this formula.</strong></a></li>
<li><a href="https://www.benzinga.com/money/100k-cd"><strong>$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</strong></a></li>
</ul>
<p>Social media tends to amplify what looks like wealth, leading to this widespread perception that everyone's swimming in money. But peek behind the scenes and it's clear that not as many people are flush with cash as it seems. So, let's break it down – how many Americans have a net worth of $1 million or more?</p>
<p><strong>Spoiler Alert: It's Not As Many As You'd Think</strong></p>
<p>According to the 2022 Survey of Consumer Finances by the Federal Reserve, only about 12% of U.S. households have a net worth over $1 million. This means that the vast majority – 88% – are nowhere near that level. Keep in mind that this is "household" net worth, which likely assumes a two-person income and combined assets.&nbsp;</p>
<p>Wealth is highly concentrated and while the average <a href="https://www.benzinga.com/personal-finance/financial-advisors/23/12/36078165/if-the-average-american-household-is-a-millionaire-with-a-net-worth-of-1-06-m">U.S. household net worth is $1.06 million</a>, the median net worth is much lower, at $192,700. Translation: A few very wealthy households are driving up the average but most people are much closer to that median number.</p>
<p><strong>Trending: ‘Beating the market through ethical real estate investing' —</strong><a href="https://www.benzinga.com/money/invest-with-roots"><strong> this platform aims to give tenants equity in the homes they live in while scoring 17.38% average annual returns for investors – here&#8217;s how to join with just $100</strong></a></p>
<p><strong>Where Are the Millionaires?</strong></p>
<p>Certain states and age groups stand out for context. New Jersey, for instance, has the highest rate of millionaire households – about 9.76% of homes there have a net worth over $1 million. Age-wise, those between 65 and 74 have the highest average net worth at $1.2 million but the median for that same group is just $266,400. In other words, while some retirees have saved a bundle, many are just getting by.</p>
<p><a href="https://www.benzinga.com/personal-finance/24/09/41075540/is-your-401-k-balance-above-average-find-out-if-youre-beating-most-savers">401(k) balances tell a similar story</a>. The average 401(k) balance for Americans aged 65 and older is $272,588 but the median is just $88,488 – meaning half of people have less than that amount saved.</p>
<p><strong>What Does It Mean to Have $1 Million?</strong></p>
<p>A net worth of $1 million isn't the same as having that amount sitting in the bank. Net worth includes assets like home equity, investments and retirement accounts – things that aren't easily converted to cash. And with inflation driving up living costs, many Americans now consider $2.2 million the new minimum to feel "wealthy."</p>
<p><strong>See Also: Can you guess how many retire with a $5,000,000 nest egg? </strong><a href="https://www.benzinga.com/money/5mil-nest-egg-adv"><strong>The percentage may shock you</strong></a><strong>.</strong></p>
<p><strong>Are We All Millionaires Yet?</strong></p>
<p>The short answer is no, not even close. And while social media may make it seem like everyone else is living in luxury, the reality is far more modest. In fact, most people are still trying to build their financial safety nets, making those few million-dollar net worthy seem rare and impressive.</p>
<p>Next time you scroll through someone's highlight reel, remember: what you see is just that – a highlight.&nbsp;</p>
<p>If you&#8217;re looking to hit that million-dollar mark yourself, it's less about flash and more about patience and steady saving. Say you're 35 and you've got $20,000 already saved. Assuming an average annual return of 7% – a common benchmark for long-term investments – you'd need to save around $5,000 a year or about $417 a month to reach $1 million by age 65. If you increase that amount as your income grows, you'll reach your goal even sooner. The key is consistency, letting time and compounding work their magic.</p>
<p>Of course, this is just one scenario and everyone's situation differs. The best way to map out your path is by <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">talking to a financial advisor</a>. They can help you customize a strategy that fits your income, goals and lifestyle, whether you're aiming for that million or a secure retirement.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>The average American couple has saved this much money for retirement —</strong><a href="http://www.benzinga.com/money/smartasset"><strong> </strong><strong>How do you compare</strong></a><strong>?</strong></li>
<li><strong>Studies show 50% of consumers think Financial Advisors cost much more than they do —</strong><a href="https://www.benzinga.com/money/money-pickle"><strong> </strong><strong>to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</strong></a></li>
</ul>


Personal Finance

Can You Guess What Percent Of People Have $1 Million Saved? Spoiler Alert – It's Far Lower Than Most Statistics Lead You To Believe

<p>In the current market session, <strong>AeroVironment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)</strong> share price is at $205.00, after a <strong>0.37%</strong> spike. Moreover, over the past month, the stock fell by <strong>7.54%</strong>, but in the past year, increased by <strong>56.33%</strong>. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1731702712_0.png" alt="Past Year Chart" /></p>

<h3>A Look at AeroVironment P/E Relative to Its Competitors</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>AeroVironment has a better P/E ratio of <strong>97.73</strong> than the aggregate P/E ratio of <strong>80.64</strong> of the Aerospace &amp; Defense industry. Ideally, one might believe that AeroVironment Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1731702712_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

Markets

AVAV

A Look Into AeroVironment Inc's Price Over Earnings

WIIM

BIOR

Biora Therapeutics shares are trading lower. The stock may be moving on continued weakness following a Q3 earnings miss and a year-over-year decline in revenue reported on Thursday

GCTS

GCT Semiconductor Holdings shares are trading lower. The company reported Q3 financial results.

ONFO

Onfolio Holdings shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

AMGN

GILD

IONS

VKTX

Shares of pharmaceutical and healthcare stocks are trading lower. The sector has been under pressure after president-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Applied Optoelectronics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AAOI, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 12 options trades for <strong>Applied Optoelectronics</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 16% bullish and 83%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $69,300, and 11, calls, for a total amount of $737,150.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $17.5 to $30.0 for Applied Optoelectronics during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Applied Optoelectronics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Applied Optoelectronics's substantial trades, within a strike price spectrum from $17.5 to $30.0 over the preceding 30 days.</p>
<h3>Applied Optoelectronics Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731701838_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$22.50</td>
<td>$122.8K</td>
<td>1.5K</td>
<td>595</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$8.2</td>
<td>$7.9</td>
<td>$7.9</td>
<td>$20.00</td>
<td>$102.3K</td>
<td>5.4K</td>
<td>680</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.35</td>
<td>$1.25</td>
<td>$1.35</td>
<td>$25.00</td>
<td>$97.4K</td>
<td>1.3K</td>
<td>781</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.8</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$20.00</td>
<td>$90.0K</td>
<td>5.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$8.0</td>
<td>$7.6</td>
<td>$7.7</td>
<td>$20.00</td>
<td>$77.0K</td>
<td>5.4K</td>
<td>840</td>
</tr>
</tbody>
</table>
</p>
<h3>About Applied Optoelectronics</h3>
<p>Applied Optoelectronics Inc is a provider of fiber-optic networking products for the Internet data center, cable television, telecommunications and fiber-to-the-home end markets. The company focuses on designing and manufacturing a range of optical communication products from components, to subassemblies, and modules to complete turn-key equipment. Demand for Applied Optoelectronics is driven by bandwidth demand in end markets. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The company derives maximum revenue from Taiwan.</p>
<p>After a thorough review of the options trading surrounding Applied Optoelectronics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Applied Optoelectronics Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,824,114, with AAOI's price down by -6.2%, positioned at $26.41.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 97 days.</li>
</ul>
<h3>What The Experts Say On Applied Optoelectronics</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $25.166666666666668.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Northland Capital Markets continues to hold a Outperform rating for Applied Optoelectronics, targeting a price of $25.<br />
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Applied Optoelectronics, maintaining a target price of $27.<br />
&#x2A; An analyst from Raymond James persists with their Outperform rating on Applied Optoelectronics, maintaining a target price of $23. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Applied Optoelectronics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

AAOI

Spotlight on Applied Optoelectronics: Analyzing the Surge in Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Zoom Video Comms</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ZM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Zoom Video Comms.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 33% bullish and 55%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $285,135, and 4 are calls, for a total amount of $366,055.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $120.0 for Zoom Video Comms during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Zoom Video Comms's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Zoom Video Comms's whale activity within a strike price range from $75.0 to $120.0 in the last 30 days. </p>
<h3>Zoom Video Comms Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731701833_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ZM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$14.95</td>
<td>$14.9</td>
<td>$14.9</td>
<td>$92.50</td>
<td>$140.0K</td>
<td>0</td>
<td align="right">94</td>
</tr>
<tr>
<td>ZM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.65</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$120.00</td>
<td>$121.0K</td>
<td>394</td>
<td align="right">384</td>
</tr>
<tr>
<td>ZM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.55</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$75.00</td>
<td>$112.0K</td>
<td>4.5K</td>
<td align="right">366</td>
</tr>
<tr>
<td>ZM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$10.0</td>
<td>$9.85</td>
<td>$9.85</td>
<td>$77.50</td>
<td>$98.5K</td>
<td>231</td>
<td align="right">100</td>
</tr>
<tr>
<td>ZM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$6.9</td>
<td>$6.0</td>
<td>$6.41</td>
<td>$85.00</td>
<td>$38.4K</td>
<td>275</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Zoom Video Comms</h3>
<p>Zoom Video Communications provides a communications platform that connects people through video, voice, chat, and content sharing. The company's cloud-native platform enables face-to-face video and connects users across various devices and locations in a single meeting. Zoom, which was founded in 2011 and is headquartered in San Jose, California, serves companies of all sizes from all industries around the world.</p>
<p>Following our analysis of the options activities associated with Zoom Video Comms, we pivot to a closer look at the company's own performance.</p>
<h3>Zoom Video Comms's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,232,484, with ZM's price down by -1.74%, positioned at $81.19.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 10 days.</li>
</ul>
<h3>Professional Analyst Ratings for Zoom Video Comms</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $85.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Zoom Video Comms, maintaining a target price of $86.<br />
&#x2A; In a positive move, an analyst from Wedbush has upgraded their rating to Outperform and adjusted the price target to $85. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Zoom Video Comms options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Spotlight on Zoom Video Comms: Analyzing the Surge in Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Danaher</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Danaher.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 18% bullish and 81%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $574,327, and 2 are calls, for a total amount of $150,000.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $210.0 to $260.0 for Danaher over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Danaher stands at 431.56, with a total volume reaching 1,664.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $210.0 to $260.0, throughout the last 30 days.</p>
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731701829_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.5</td>
<td>$11.0</td>
<td>$11.2</td>
<td>$230.00</td>
<td>$163.5K</td>
<td>1.3K</td>
<td align="right">139</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.9</td>
<td>$4.3</td>
<td>$4.9</td>
<td>$230.00</td>
<td>$147.0K</td>
<td>1.1K</td>
<td align="right">300</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$44.8</td>
<td>$42.7</td>
<td>$44.1</td>
<td>$230.00</td>
<td>$110.2K</td>
<td>0</td>
<td align="right">25</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$210.00</td>
<td>$62.8K</td>
<td>126</td>
<td align="right">699</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$31.6</td>
<td>$30.2</td>
<td>$30.7</td>
<td>$260.00</td>
<td>$61.4K</td>
<td>205</td>
<td align="right">30</td>
</tr>
</tbody>
</table>
</p>
<h3>About Danaher</h3>
<p>In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.</p>
<p>After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Danaher</h3>
<ul>
<li>With a trading volume of 3,258,575, the price of DHR is down by -1.73%, reaching $235.23.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>Expert Opinions on Danaher</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $288.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Danaher, which currently sits at a price target of $315.<br />
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Danaher, maintaining a target price of $275.<br />
&#x2A; An analyst from Baird persists with their Outperform rating on Danaher, maintaining a target price of $277.<br />
&#x2A; An analyst from Stifel persists with their Hold rating on Danaher, maintaining a target price of $265.<br />
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Danaher, targeting a price of $310. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Danaher, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


What the Options Market Tells Us About Danaher

<p><a href="https://www.youtube.com/watch?v=OAHHA27td-A" title="https://www.youtube.com/watch?v=OAHHA27td-A">https://www.youtube.com/watch?v=OAHHA27td-A</a><br />&nbsp;</p>


Federal Reserve

Fed's Barkin Says Taking Univerted Yield Curve As Good News; Since Fed Began Cutting Rates, Demand Data Has Come In Stronger; We Don't Control The Long-End Of The Yield Curve

<p>Cryptocurrency markets are closing the week strong, with Bitcoin pushing above $90,000 at the end of the U.S. trading session.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td> $90,792</td>
<td>+1.5%</td>
</tr>
<tr>
<td><strong>Ethereum </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td> $3,061  </td>
<td>-2.3%</td>
</tr>
<tr>
<td><strong>Solana</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td> $213.8</td>
<td>-0.5%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td> $0.3719</td>
<td>-5.1%</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td> $0.00002439</td>
<td>-2.7%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul>
<li>IntoTheBlock data shows large transaction volume falling by 14% and daily active addresses dropping by 3%. </li>
<li>Coinglass data reports $453 million in liquidations, $288 million of which were liquidated long positions.</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42007247/bitcoin-dogecoin-success-driven-by-narrative-and-momentum-report-argues">Bitcoin, Dogecoin Success Driven By &#8216;Narrative And Momentum,&#8217; Report Argues</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011875/solana-ripple-litecoin-etfs-may-be-on-the-table-under-trump-administration-industry-experts-think">Solana, Ripple, Litecoin ETFs May Be On The Table Under Trump Administration, Industry Experts Say</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42012609/xrp-soars-58-on-the-week-what-is-going-on">XRP Soars 58% On The Week: What Is Going On?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014985/matt-gaetz-to-be-confirmed-as-attorney-general-in-a-trump-administration-not-so-fast-polymarket-traders-say">Matt Gaetz To Be Confirmed As Attorney General In A Trump Administration? Not So Fast, Polymarket Traders Say</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014810/viral-baby-hippo-moodeng-makes-new-all-time-high-could-follow-shiba-inus-run-trader-predicts">Viral Baby Hippo MOODENG Makes New All-Time High, Could Follow Shiba Inu&#8217;s Run, Trader Predicts</a></li>
</ul>
<p><strong>Top Gainers:</strong></p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td><strong>Flare</strong> (CRYPTO: FLR)</td>
<td> $0.0207</td>
<td>46.5%</td>
</tr>
<tr>
<td><strong>Algorand  </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/algo/usd">ALGO</a>)</td>
<td> $0.1805</td>
<td>20.5%</td>
</tr>
<tr>
<td><strong>Cardano </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td> $0.6784</td>
<td>20.2%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>Veteran analyst Benjamin Cowen expects Bitcoin dominance to increase for the remainder of the year. He expects a reversal only in 2025.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">With <a href="https://twitter.com/hashtag/ALT?src=hash&amp;ref_src=twsrc%5Etfw">#ALT</a> / <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> pairs still about 27% off their lows, <a href="https://twitter.com/hashtag/DXY?src=hash&amp;ref_src=twsrc%5Etfw">#DXY</a> climbing, yields going up, and QT continuing, <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> dominance will likely go higher into EOY. <br /><br />I do think <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> dominance will go down in 2025, but that is 1.5 months away, and a lot can happen between now and then. <a href="https://t.co/9xosZy9y9N">pic.twitter.com/9xosZy9y9N</a></p>
<p>&mdash; Benjamin Cowen (@intocryptoverse) <a href="https://twitter.com/intocryptoverse/status/1857501824523059392?ref_src=twsrc%5Etfw">November 15, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>A poll by trader TheFlowHorse shows his audience divided over whether Bitcoin will trade above $89,500 on the weekend, with a slight 54% majority <a href="https://twitter.com/TheFlowHorse/status/1857488508207902978">saying</a> yes.</p>
<p>Technical analyst Pierre outlined the likely paths for Bitcoin in the short term: either a flip of the resistance level around $90,000, which could lead to new highs, or a visit to the bottom of the range around $85,000. In between the two prices, he <a href="https://x.com/pierre_crypt0/status/1857394755539235126">expects</a> sideways trading action.</p>
<p><strong>What&#8217;s Next</strong>: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$ALGO

$BTC

$DOGE

$ETH

$FLR

$SHIB

$SOL

Bitcoin Pushes Back Above $90,000, Ethereum, Dogecoin Lag To End A Record Week

<p><a href="https://www.youtube.com/watch?v=OAHHA27td-A" title="https://www.youtube.com/watch?v=OAHHA27td-A">https://www.youtube.com/watch?v=OAHHA27td-A</a></p>


Fed's Barkin Says Low-Hiring, Low-firing Environment Will Give Way To Something Else; Not Hearing Layoffs On Any Scale; We Are Restrictive Enough; Hard To Know If Very, Or Somewhat, Or A Little Restrictive; We Can Recalibrate Rates To A Somewhat Less Restrictive Level; So Much Data Between Now And December

Fed's Barkin  Always Have Expected Core PCE Would Stay In The High Twos In H2; I Am Still Seeing Progress On Inflation; Pricing Power Is Getting More Limited; I Hope That In Q1 Inflation Numbers Will Come Down; It's My Expectation As Well; We Are A Long Way From Know What Will Happen With Tariffs, Hard To Know The Impact

<p><a href="https://truthsocial.com/@realDonaldTrump/113488754953884936" title="https://truthsocial.com/@realDonaldTrump/113488754953884936">https://truthsocial.com/@realDonaldTrump/113488754953884936</a></p>


Politics

General

President-elect Trump Nominates North Dakota Governor, Doug Burgum, To Join Administration As Secretary Of The Interior And As Chairman Of Newly Formed National Energy Council

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Baidu</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BIDU, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Baidu.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 70% bullish and 30%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $734,906, and 12 are calls, for a total amount of $564,254.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $120.0 for Baidu over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Baidu's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Baidu's significant trades, within a strike price range of $75.0 to $120.0, over the past month.</p>
<h3>Baidu 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700888_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$38.35</td>
<td>$38.0</td>
<td>$38.0</td>
<td>$120.00</td>
<td>$228.0K</td>
<td>376</td>
<td>60</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$75.00</td>
<td>$176.7K</td>
<td>5.8K</td>
<td>511</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.6</td>
<td>$16.35</td>
<td>$16.52</td>
<td>$100.00</td>
<td>$82.6K</td>
<td>2.5K</td>
<td>56</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.55</td>
<td>$2.53</td>
<td>$2.55</td>
<td>$90.00</td>
<td>$76.2K</td>
<td>3.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.55</td>
<td>$2.5</td>
<td>$2.51</td>
<td>$90.00</td>
<td>$75.2K</td>
<td>3.6K</td>
<td>715</td>
</tr>
</tbody>
</table>
</p>
<h3>About Baidu</h3>
<p>Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.</p>
<p>Following our analysis of the options activities associated with Baidu, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Baidu</h3>
<ul>
<li>Currently trading with a volume of 1,780,410, the BIDU's price is up by 0.47%, now at $84.45. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About Baidu</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $115.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Baidu, targeting a price of $115. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Baidu options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


BIDU

Check Out What Whales Are Doing With BIDU

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Albemarle</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALB, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Albemarle.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 33% bullish and 58%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $645,810, and 3 are calls, for a total amount of $127,222.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $110.0 for Albemarle during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Albemarle options trades today is 1266.0 with a total volume of 2,294.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Albemarle's big money trades within a strike price range of $95.0 to $110.0 over the last 30 days.</p>
<h3>Albemarle Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700884_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.85</td>
<td>$11.6</td>
<td>$11.65</td>
<td>$95.00</td>
<td>$291.2K</td>
<td>790</td>
<td align="right">250</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.95</td>
<td>$12.9</td>
<td>$12.9</td>
<td>$110.00</td>
<td>$101.9K</td>
<td>2.9K</td>
<td align="right">341</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$7.75</td>
<td>$7.6</td>
<td>$7.62</td>
<td>$100.00</td>
<td>$57.1K</td>
<td>1.4K</td>
<td align="right">219</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$13.0</td>
<td>$12.7</td>
<td>$12.85</td>
<td>$110.00</td>
<td>$43.6K</td>
<td>2.9K</td>
<td align="right">407</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.65</td>
<td>$13.55</td>
<td>$13.65</td>
<td>$110.00</td>
<td>$42.3K</td>
<td>2.9K</td>
<td align="right">81</td>
</tr>
</tbody>
</table>
</p>
<h3>About Albemarle</h3>
<p>Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.</p>
<p>Following our analysis of the options activities associated with Albemarle, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Albemarle Standing Right Now?</h3>
<ul>
<li>With a volume of 1,232,520, the price of ALB is down -0.61% at $101.48. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 89 days.</li>
</ul>
<h3>What The Experts Say On Albemarle</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $127.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Albemarle with a target price of $170.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Albemarle with a target price of $127.<br />
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Albemarle, targeting a price of $79.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Albemarle, which currently sits at a price target of $133. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Albemarle options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in Albemarle

<p>In the last three months, 10 analysts have published ratings on Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $120.3, a high estimate of $142.00, and a low estimate of $105.00. This upward trend is evident, with the current average reflecting a 11.39% increase from the previous average price target of $108.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700881_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Morgan Stanley among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$142.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$122.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$107.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$121.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$112.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Saul Martinez</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$118.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$105.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Morgan Stanley. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Morgan Stanley compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Morgan Stanley's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Morgan Stanley's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Morgan Stanley analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Morgan Stanley</h2>
<p>Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.</p>
<h3>A Deep Dive into Morgan Stanley's Financials</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Morgan Stanley's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>15.47%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Morgan Stanley's net margin excels beyond industry benchmarks, reaching <strong>21.12%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Morgan Stanley's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.26%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Morgan Stanley's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.25%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Morgan Stanley's debt-to-equity ratio surpasses industry norms, standing at <strong>3.37</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Beyond The Numbers: 10 Analysts Discuss Morgan Stanley Stock

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>BioNTech</strong>.</p>
<p>Looking at options history for BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 54% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $442,050 and 4, calls, for a total amount of $353,063.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $92.5 and $120.0 for BioNTech, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of BioNTech stands at 369.29, with a total volume reaching 2,574.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in BioNTech, situated within the strike price corridor from $92.5 to $120.0, throughout the last 30 days.</p>
<h3>BioNTech Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700878_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$23.6</td>
<td>$19.7</td>
<td>$23.6</td>
<td>$115.00</td>
<td>$160.4K</td>
<td align="right">140</td>
<td align="right">129</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.5</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$120.00</td>
<td>$105.9K</td>
<td align="right">108</td>
<td align="right">261</td>
</tr>
<tr>
<td>BNTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.6</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$105.00</td>
<td>$88.4K</td>
<td align="right">818</td>
<td align="right">429</td>
</tr>
<tr>
<td>BNTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$12.3</td>
<td>$11.5</td>
<td>$12.3</td>
<td>$110.00</td>
<td>$67.6K</td>
<td align="right">921</td>
<td align="right">55</td>
</tr>
<tr>
<td>BNTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$11.6</td>
<td>$11.3</td>
<td>$11.6</td>
<td>$110.00</td>
<td>$64.9K</td>
<td align="right">921</td>
<td align="right">489</td>
</tr>
</tbody>
</table>
</p>
<h3>About BioNTech</h3>
<p>BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.</p>
<h3>Current Position of BioNTech</h3>
<ul>
<li>With a volume of 2,881,741, the price of BNTX is down -3.1% at $100.35. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 124 days.</li>
</ul>
<h3>Expert Opinions on BioNTech</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $135.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan persists with their Neutral rating on BioNTech, maintaining a target price of $124.<br />
&#x2A; An analyst from Goldman Sachs has elevated its stance to Buy, setting a new price target at $137.<br />
&#x2A; An analyst from TD Cowen persists with their Hold rating on BioNTech, maintaining a target price of $122.<br />
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on BioNTech with a target price of $171.<br />
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Hold rating for BioNTech, targeting a price of $122. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest BioNTech options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


BNTX

BioNTech's Options: A Look at What the Big Money is Thinking

<p>In the preceding three months, 4 analysts have released ratings for Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $63.5, a high estimate of $75.00, and a low estimate of $49.00. This current average has not changed from the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700865_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Silence Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Silence Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Silence Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Silence Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Silence Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SLN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Silence Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Silence Therapeutics</h2>
<p>Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.</p>
<h3>Silence Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Silence Therapeutics faced challenges, resulting in a decline of approximately <strong>-93.43%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Silence Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-2602.34%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Silence Therapeutics's ROE excels beyond industry benchmarks, reaching <strong>-13.17%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Silence Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-8.13%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Silence Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.0</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 4 Ratings For Silence Therapeutics

Buybacks

FSBW

FS Bancorp Completes $5M Share Repurchase Program And Authorizes Additional $5M Buyback To Run Through October 2025

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning!</p>



<p>Moving stocks this morning are pharmaceutical updates, earnings reports, collaboration agreements and more.</p>



<p>Let&rsquo;s get into that news down below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Stoke Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/stok-stock-quote/"><strong>STOK</strong></a>) stock is rocketing more than 81% alongside <a href="https://www.nasdaq.com/press-release/stoke-therapeutics-announces-landmark-new-data-that-support-the-potential-for-stk-001">positive Phase 1/2a studies data</a>.</li>



<li><strong>Check-Cap</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/chek-stock-quote/"><strong>CHEK</strong></a>) shares are soaring over 35% after announcing a <a href="https://www.nasdaq.com/press-release/nobul-ai-corp-and-check-cap-ltd-enter-into-definitive-business-combination-agreement">business combination agreement</a>.</li>



<li><strong>OpGen </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/opgn-stock-quote/"><strong>OPGN</strong></a>) stock is surging more than 30% after announcing the <a href="https://ir.opgen.com/news-releases/news-release-details/opgen-announces-acquisition-preferred-stock-david-lazar">acquisition of its preferred shares</a>.</li>



<li><strong>C3is </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ciss-stock-quote/"><strong>CISS</strong></a>) shares are rising over 25% as it <a href="https://c3is.pro/c3is-inc-announces-the-date-for-the-release-of-the-fourth-quarter-and-twelve-months-2023-financial-and-operating-results/investor-relations/press-releases/">prepares to release earnings</a>.</li>



<li><strong>Krispy Kreme</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dnut-stock-quote/"><strong>DNUT</strong></a>) stock is increasing more than 22% on <a href="https://www.cnbc.com/2024/03/26/mcdonalds-to-sell-krispy-kreme-doughnuts-nationwide-by-end-of-2026.html">a collaboration with <strong>McDonald&rsquo;s</strong></a><strong> </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/mcd-stock-quote/"><strong>MCD</strong></a>).</li>



<li><strong>Mesoblast</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/meso-stock-quote/"><strong>MESO</strong></a>) shares are gaining over 21% alongside <a href="https://www.nasdaq.com/press-release/united-states-food-drug-administration-fda-notifies-mesoblast-that-available-clinical">an update on a drug submission</a>.</li>



<li><strong>Allarity Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/"><strong>ALLR</strong></a>) stock is climbing more than 16% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318185017&amp;type=PDF&amp;symbol=ALLR&amp;cdn=4c6b3ee332556111dd440255ac861084&amp;companyName=Allarity+Therapeutics+Inc.&amp;formType=S-8&amp;formDescription=Registration+statement+under+Securities+Act+of+1933+to+be+offered+to+employees+pursuant+to+certain+plans&amp;dateFiled=2024-03-25">updating its Equity Incentive Plan</a>.</li>



<li><strong>Intelligent </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/intj-stock-quote/"><strong>INTJ</strong></a>) shares are getting an over 14% boost without any clear news this morning.</li>



<li><strong>60 Degrees</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/"><strong>SXTP</strong></a>) stock is jumping more than 14% on Tuesday morning.</li>



<li><strong>XTL Biopharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtlb-stock-quote/"><strong>XTLB</strong></a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Tidal Trust II YieldMax MRNA Option Income Strategy ETF </strong>(NYSEARCA:<span><a href="https://investorplace.com/stock-quotes/mrny-stock-quote/"><strong>MRNY</strong></a></span>) stock is plummeting 60% this morning.</li>



<li><strong>NeuBase Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nbse-stock-quote/"><strong>NBSE</strong></a>) shares are crashing more than 54% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318184533&amp;type=PDF&amp;symbol=NBSE&amp;cdn=3014c60622ce95fc448919cc3936cd2b&amp;companyName=NeuBase+Therapeutics+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-03-25">special shareholder meeting</a>.</li>



<li><strong>AppTech Payments</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/apcx-stock-quote/"><strong>APCX</strong></a>) stock is diving close to 43% after <a href="https://www.nasdaq.com/press-release/apptech-payments-corp.-announces-proposed-underwritten-public-offering-of-common">proposing a share offering</a>.</li>



<li><strong>The Real Good Food</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgf-stock-quote/"><strong>RGF</strong></a>) shares are dropping over 19% on Tuesday.</li>



<li><strong>Next e GO</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/egox-stock-quote/"><strong>EGOX</strong></a>) stock is taking a more than 18% beating <a href="https://investorplace.com/2024/03/why-is-next-e-go-egox-stock-up-86-today/">after a recent rally</a>.</li>



<li><strong>eFFECTOR Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/"><strong>EFTR</strong></a>) shares are tumbling over 18% alongside its <a href="https://finance.yahoo.com/news/effector-therapeutics-reports-fourth-quarter-200100641.html">latest earnings report</a>.</li>



<li><strong>Tivic Health Systems</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/"><strong>TIVC</strong></a>) stock is decreasing more than 16% with the release of its <a href="https://investorplace.com/earning-results/2024/03/tivc-stock-earnings-tivic-health-systems-for-q4-of-2023/">Q4 earnings report</a>.</li>



<li><strong>Kaival Brands Innovations</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/"><strong>KAVL</strong></a>) shares are sliding over 12% after releasing its <a href="https://www.marketscreener.com/quote/stock/KAIVAL-BRANDS-INNOVATIONS-111314401/news/Kaival-Brands-Innovations-Group-Inc-Reports-Earnings-Results-for-the-First-Quarter-Ended-January-3-46281052/">most recent earnings report</a>.</li>



<li><strong>Tuniu </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/tour-stock-quote/"><strong>TOUR</strong></a>) stock is falling more than 10% this morning.</li>



<li><strong>Westport Fuel Systems </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/wprt-stock-quote/"><strong>WPRT</strong></a>) shares close out our pre-market stock movers down over 10% <a href="https://seekingalpha.com/article/4680367-westport-fuel-systems-stock-q4-earnings-review-maintain-hold">alongside Q4 earnings</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/03/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-march-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The <strong>Nasdaq</strong> is one of the most closely watched indexes for every investor to follow. The Nasdaq, which is an acronym for the National Association of Securities Dealers Automated Quotations, is an exchange comprised of more than 3,400 individual securities. Many of these stocks are in the technology sector including the Magnificent 7 stocks.&nbsp;With that trend unlikely to change, it&rsquo;s a good time to look at the best Nasdaq stocks to buy in April. &nbsp;</p>



<p>The Nasdaq exchange was launched in 1971 to create an avenue for new, emerging companies to trade on the stock market.&nbsp;Also, it was the first U.S. stock exchange to allow online trading, which attracted <a href="https://investorplace.com/industries/technology/">technology stocks</a> that viewed the exchange as more modern. &nbsp;</p>



<p>Because of its heavy weighting toward technology stock, Nasdaq stocks are popular with growth-oriented investors. However, you can find stocks in virtually every sector of the market. </p>



<p>So now, let&rsquo;s explore three stocks from outside the tech sector. Each has high short-term upside that puts them among the best Nasdaq stocks to buy in April. &nbsp;</p>



<h2>Microvast (MVST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/battery-power-vector-300x169.png" alt="A vector illustration of a battery with neon lines swirling it; forever battery. promising battery stocks"><div>Source: MarySan / Shutterstock</div></div><p><strong>Microvast</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mvst-stock-quote/"><strong>MVST</strong></a></span>) hearkens back to the early days of the Nasdaq exchange. The company only went public in 2021. MVST stock is down 60% in the last six months, the company is not yet profitable, and the stock trades for just 59 cents per share as of the market close on April 2, 2024. Oh, and short interest is up about 13% in the last month and about 14% of the total float. &nbsp;</p>



<p>However, Microvast provides the essential technology needed to make electric vehicle (<strong>EV</strong>) batteries. In fact, the company is part of every stage of the process including manufacturing. It currently has three battery manufacturing plants in operation. </p>



<p>On April 1, Microvast beat analyst expectations on the top and bottom lines. Revenue of $104.58 million was 10.7% higher than estimates and nearly 50% higher year-over-year.&nbsp;</p>



<p>However, the company is also <a href="https://investorplace.com/2023/08/7-ev-stocks-with-huge-potential-you-can-buy-with-zero-regrets/" target="_blank">burning through cash</a>, and that shows no signs of stopping. In the company&rsquo;s earnings report, it said it <a href="https://ir.microvast.com/static-files/b7a7ff65-c64b-42bb-90ff-59408839514d" target="_blank">will need funding</a> to complete construction on a fourth manufacturing plant in Tennessee. This could be something for shareholders to watch in the short term. However, analysts don&rsquo;t appear to be phased. They remain bullish on the stock and give it a 493% upside from its current price. &nbsp;</p>



<h2>Piedmont Lithium (PLL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/11/pll1600-300x169.png" alt="Person holding cellphone with logo of US mining company Piedmont Lithium Inc. (PLL) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p>If you&rsquo;re looking for an even more picks-and-shovel play on the emerging need for lithium, <strong>Piedmont Lithium</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pll-stock-quote/"><strong>PLL</strong></a></span>) takes you right to the source. Mining stocks were hit hard as the supply of lithium outpaced demand in 2023. As a reflection of that supply-demand imbalance, PLL stock is down 77% in the last 12 months.</p>



<p>However, that cycle appears to be reversing. The key takeaway for investors comes down to location. Piedmont is one of the leading North American lithium miners. This coincides to a time when the U.S. Congress is looking for ways to bring the lithium supply chain closer to home.&nbsp;</p>



<p>Further, Piedmont has an operational lithium mine in Quebec with two other assets in development. At <a href="https://investorplace.com/2024/03/from-six-figures-to-seven-3-lithium-stocks-set-to-make-millionaires/" target="_blank">peak production</a>, the company is targeting 525,000tpy of spodumene concentrate and 60,000tpy of lithium hydroxide. As lithium prices increase, PLL stock is setting up to be an easy multibagger stock in coming years. &nbsp;</p>



<h2>Real Good Food (RGF)</h2>



<a href="https://investorplace.com/wp-content/uploads/2020/10/healthy-food.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/healthy-food-300x169.jpg" alt="Healthy food including salmon, almonds, garlic, broccoli, avocado, and lettuce"></a><p>At first glance, <strong>Real Good Food</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rgf-stock-quote/"><strong>RGF</strong></a></span>) is an odd choice as one of the best Nasdaq stocks to buy in April. The stock is down over 91% in the last 12 months. And, it trades for just 37 cents per share after <a href="https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/" target="_blank">diluting its stock</a> in October 2023. &nbsp;</p>



<p>Plus, the company is trying to occupy a niche of healthy frozen food that doesn&rsquo;t have much of a moat. But, it is in channels such as <strong>Costco</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cost-stock-quote/"><strong>COST</strong></a></span>) and <strong>Sam&rsquo;s Club</strong>. Additionally, the company is generating revenue which has increased year over year (<strong>YOY</strong>) in the last two quarters. &nbsp;</p>



<p>Now to help it turn a profit, Real Good Food is <a href="https://investors.realgoodfoods.com/news-releases/news-release-details/real-good-food-company-announces-leadership-changes-and-supply" target="_blank">making a change in the C-suite</a>. Tim Zimmer, the former chief marketing officer at <strong>Smithfield Foods</strong> is taking over as CEO. He most recently helped Smithfield turn around its Sara Lee Fresh Bakery division. &nbsp;</p>



<p>Investors will hear from Zimmer for the first time when the company reports earnings in May. But analysts remain bullish on RGF stock with a consensus price target of $4.75, an increase of 11,73% from its current price. &nbsp;</p>



<p><em>On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em>&nbsp;</p>



<p> &nbsp;</p>
<div><p>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/the-3-best-nasdaq-stocks-to-buy-in-april-2024/">The 3 Best Nasdaq Stocks to Buy in April 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 3 Best Nasdaq Stocks to Buy in April 2024

The Real Good Food Company receives Nasdaq notice of non-compliance

Medifast, Beauty Health among consumer staples additions in Russell Microcap; PLBY Group, Rocky Mountain Chocolate removed

The Real Good Food Company gets Nasdaq notice regarding filing requirements

GPRO, IRBT among notable consumer discretionary additions to Russell Microcap; PLBY, RMCF out

Warning: RGF is at high risk of performing badly

The Real Good Food Company receives Nasdaq notice regarding filing requirements

The Real Good Food Company receives Nasdaq's potential delisting notice

Real Good Food Company, Inc. Class A ( ($RGF) ) has issued an update. Real Good Foods has revamped its financial structure by consolidating existin...

Real Good Foods Bolsters Growth with Strategic Financial Moves

ALLR

APCX

AXIL

BHIL

CBUS

CENN

CHEK

CISS

COSM

COST

DNUT

EFTR

EGOX

FLNT

FLYX

FTLF

GOEV

GPRO

GROV

HOUR

INTJ

IRBT

KAVL

MESO

MRNY

MULN

MVST

NBSE

NCMI

OPGN

OWLT

PLBY

PNST

RCAT

RMCF

SANW

SAVE

SBEV

SERV

SGRP

SKIN

SOAR

SOND

SPRU

STOK

SXTP

TIVC

TOUR

VCSA

WPRT

WVVI

XTLB

ZVIA

Restaurants

Press Releases

The Real Good Food Company to Participate in the 36th Annual ROTH Conference

Management

The Real Good Food Company Announces Leadership Changes and Supply Chain Optimization

The Real Good Food Company Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

The Real Good Food Company Appoints New Senior Food Executives to Lead Finance, Procurement, Supply Chain and Business Management

The Real Good Food Company to Participate in the 24th Annual B. Riley Institutional Investor Conference

The Real Good Food Company Receives Nasdaq Notice Regarding Filing Requirements

Real Good Foods Launches New Seasoned Chicken Breast Chunks in 4,000 Walmart Stores Nationwide

Health Care

The Real Good Food Company Receives Nasdaq Notice Regarding Potential Delisting

Financing

The Real Good Food Company Announces Debt Refinancing Transactions with PMC Financial Services and Emblem Investments Fund I, LP

Branchout Food

Barfresh Food Group

Blue Star Foods

Better Choice Co

Australian Oilseeds Holdings Limited - Ordinary Shares

Australian Oilseeds Hldgs

DDC Enterprise Limited Class A Ordinary Shares

DDC Enterprise

Farmmi

Farmer Bros

CIMG

Coffee Holding Co

Moolec Science

TDH Hldgs

Planet Green Holdings

Real Good Food Co

Rocky Mountain Chocolate Factory, Inc. - Common Stock

Rocky Mountain Chocolate

Stryve Foods, Inc. - Class A Common Stock

Stryve Foods

Sow Good

Steakholder Foods Ltd. - American Depositary Shares

Steakholder Foods

Top Wealth Group Holding Limited - Ordinary Shares

Top Wealth Group

B. Riley Securities

Truist Securities

Roth MKM

Roth Capital

Jefferies

R&G Fincl

<p><strong>리얼 굿 푸드 컴퍼니</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) 주식은 회사가 <strong>PMC 파이낸셜 서비스</strong> 및 <strong>엔블럼 인베스트먼트 펀드</strong>(Emblem Investment Fund)와의 부채 재융자 거래를 발표한 후 목요일 시간외 거래에서 70% 이상 급등했다. 이는 <a href="https://www.benzinga.com/pressreleases/24/09/g41055786/the-real-good-food-company-announces-debt-refinancing-transactions-with-pmc-financial-services-and" target="_blank" rel="noopener" data-google-interstitial="false">6,000만 달러의 새로운 장기 대출</a>을 위한 거래이다.</p>
<p><strong>세부 사항:</strong> 이 회사는 수익금 중 800만 달러를 기존 PMC 자금 상환에 사용하고 5,200만 달러를 거래 수수료 및 일반 기업 운영 자금으로 사용하여 제조 능력 확장과 여러 기업 이니셔티브를 지원하여 회사의 수익성 있는 장기 성장을 위한 기반을 마련한다고 밝혔다.</p>
<p>또한, 이 거래의 일환으로 이 회사는 엔블럼(Emblem)에 자회사인 리얼 굿 푸드 LLC(Real Good Food LLC)의 클래스 C 유닛 형태로 발행된 19.99%의 미상장 주식을 발행하여 이 회사의 보통주로 교환할 수 있도록 하였다.</p>
<p><em><strong>다음 읽기:</strong> <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41036580/expect-healthy-online-spending-this-holiday-season-says-analyst-what-to-know"><strong>올해 연휴 시즌에 건강한 온라인 지출을 기대하세요, 애널리스트가 말합니다: 알아야 할 사항</strong></a></em></p>
<p>&#8220;우리는 이러한 혁신적인 거래를 발표하게 되어 매우 기쁘다. 이는 우리에게 상당한 유동성을 제공하고 공급망 및 전략적 이니셔티브에 대한 중요한 투자를 할 수 있는 능력을 제공한다. 이는 우리 공급망을 강화하여 제품에 대한 강한 수요를 충족하고 고객 서비스 향상에 기여하여 수익성 있는 장기 성장을 위한 기반을 마련한다&#8221;고 리얼 굿 푸드의 CEO인 <strong>팀 짐머</strong>(Tim Zimmer)가 말했다.</p>
<p><a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>의 데이터에 따르면, 리얼 굿 푸드의 주가는 발표 이후에 760만 주 이상이 거래된 중량 거래량을 바탕으로 움직이고 있다.</p>
<p><strong>RGF 주가 움직임:</strong> <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>에 따르면, 리얼 굿 푸드의 주식은 목요일 애프터 아워에서 72.84% 상승한 64센트로 거래되었다.</p>
<p><em><strong>추가 읽기:</strong></em></p>
<ul>
<li><em><a href="https://www.benzinga.com/news/24/09/41028294/whats-going-on-with-snowflake-stock"><strong>스노우플레이크 주식에 무슨 일이 벌어지고 있나요?</strong></a></em></li>
</ul>
<p><em>사진: Gerd Altmann from Pixabay</em></p>
<p><strong>Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요</strong><br />
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요.<br />
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener"><strong>여기를 클릭</strong></a>하여 14일 무료 체험을 시작하세요.</p>

Comments

Real Good Food Co

뉴스

에 대한 최신 뉴스 Real Good Food Co (NASDAQ:RGF) 주식

목요일, 9월 26, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌